Background

The MFDS conducts an annual public meeting to review the financial transparency and efficiency of the Prescription Drug User Fee Act (PDUFA), Biosimilar User Fee Act (BPUFA), and Generic User Fee Act (GDUFA). Recent drug price increases and heightened policy pressure have amplified calls for fairness and efficiency in the fee system. Accordingly, the MFDS seeks stakeholder input to develop improvement proposals.

Key Topics

The meeting will present a financial transparency report and discuss potential adjustments to the fee structure. Specific proposals will be offered on how to measure and disclose fee collection, utilization, and efficiency metrics. This information is critical for both pharmaceutical/biotech companies and patient advocacy groups.

Industry Impact

Pharma and biotech firms will be able to precisely assess fee burdens and recalibrate cost‑management strategies. Transparent financial reporting reduces regulatory risk and enables early anticipation of possible fee increases. Moreover, clearer fee utilization is expected to strengthen collaborative relationships with the MFDS.

Patients and Market

If fees are used efficiently, review timelines for new drugs can be accelerated, allowing patients faster access to novel therapies. Conversely, continued inefficiencies could heighten price‑increase pressures, undermining market price stability. Thus, enhanced transparency supports both patient welfare and market confidence.

Outlook

Based on the meeting outcomes, the MFDS will regularly update fee policies and publish concrete improvement measures incorporating stakeholder feedback. In the long term, this could reshape the cost structure and regulatory landscape of the pharma/biotech sector. Investors and researchers should continuously monitor these policy developments.